These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33105170)

  • 1. Treatment of Opioid Use Disorder Attributed to Fentanyl With High-Dose Buprenorphine: A Case Report.
    Baca-Atlas MH; Williams JB
    J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):83-85. PubMed ID: 33105170
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on Koltzenburg et al.: Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 2006;126:165-74.
    Angst MS; Clark DJ
    Pain; 2007 Apr; 128(3):292-294. PubMed ID: 17276008
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence.
    Wakeman SE; Chang Y; Regan S; Yu L; Flood J; Metlay J; Rigotti N
    J Addict Med; 2019; 13(4):253-257. PubMed ID: 30550392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.
    Koltzenburg M; Pokorny R; Gasser UE; Richarz U
    Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New drugs for substitution treatment of opioid dependence. Buprenorphine and 1-alpha-acetylmethadol (LAAM) ].
    Petersen H; Skauge L; Svejsø J; Ege PP
    Ugeskr Laeger; 2000 Nov; 162(48):6553-6. PubMed ID: 11187226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No potentiation of fentanyl by use of transdermal buprenorphine in patients undergoing fast-track anesthesia for open-heart surgery.
    Freye E; Hartung E; Levy JV
    J Opioid Manag; 2005; 1(3):162-7. PubMed ID: 17315420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Is anti-hyperalgesia clinically relevant? Dosage increase is hardly necessary].
    MMW Fortschr Med; 2006 Jan; 148(1-2):43. PubMed ID: 16610415
    [No Abstract]   [Full Text] [Related]  

  • 9. Direct rotation from a fentanyl patch to a buprenorphine patch in a patient with chronic pain.
    Steenhof N; Flannery J; Lee J
    J Opioid Manag; 2024; 20(3):260-262. PubMed ID: 39017618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Post-Cesarean Section Opioid Analgesic Requirements in Women With Opioid Use Disorder Treated With Methadone or Buprenorphine.
    Vilkins AL; Bagley SM; Hahn KA; Rojas-Miguez F; Wachman EM; Saia K; Alford DP
    J Addict Med; 2017; 11(5):397-401. PubMed ID: 28727661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Analgesic Patches in Cynomolgus Macaques (
    Smith AA; Halliday LC; Lindeblad MO; Fortman JD
    J Am Assoc Lab Anim Sci; 2019 May; 58(3):356-361. PubMed ID: 31010456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
    Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
    J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats.
    Dahan A; Yassen A; Bijl H; Romberg R; Sarton E; Teppema L; Olofsen E; Danhof M
    Br J Anaesth; 2005 Jun; 94(6):825-34. PubMed ID: 15833777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating Fentanyl Withdrawal.
    Neimark G; Tjoa C
    J Behav Health Serv Res; 2020 Oct; 47(4):614-615. PubMed ID: 32435865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
    Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
    J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letters.
    Ulster Med J; 2016 Sep; 85(3):203-210. PubMed ID: 27698525
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of ascending buprenorphine doses on measures of experimental pain: A pilot study.
    Nielsen S; Rivas C; Demirkol A; Lintzeris N
    J Subst Abuse Treat; 2019 Sep; 104():128-134. PubMed ID: 31370976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients.
    Moss LM; Algera MH; Dobbins R; Gray F; Strafford S; Heath A; van Velzen M; Heuberger JAAC; Niesters M; Olofsen E; Laffont CM; Dahan A; Groeneveld GJ
    PLoS One; 2022; 17(1):e0256752. PubMed ID: 35085249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Cannabis Use Influence Opioid Outcomes and Quality of Life Among Buprenorphine Maintained Patients? A Cross-sectional, Comparative Study.
    Bagra I; Krishnan V; Rao R; Agrawal A
    J Addict Med; 2018; 12(4):315-320. PubMed ID: 29543612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.